SequelSEC

OCULAR THERAPEUTIX, INC OCUL

Pharmaceutical Preparations · CIK 0001393434 · Fiscal year ends 1231

Revenue
$51.95M
Fiscal year ended 2025-12-31
Operating income
-$270.02M
Fiscal year ended 2025-12-31
Free cash flow
-$216.89M
Fiscal year ended 2025-12-31

OCULAR THERAPEUTIX, INC (OCUL) reported revenue of $51.95M and net income of -$265.94M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from OCULAR THERAPEUTIX, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

OCULAR THERAPEUTIX, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$51.95M$63.72M$58.44M$51.49M$43.52M$17.40M$4.23M$1.99M$1.92M$1.89M
Cost of revenue$6.57M$5.63M$5.28M$4.54M$4.41M$2.08M$2.32M$465.00K$457.00K$443.00K
Gross profit$45.38M$58.10M$53.16M$46.95M$39.12M$15.32M$1.90M$1.52M$1.47MUnavailable
Operating income-$270.02M-$171.78M-$82.38M-$78.65M-$78.04M-$62.85M-$85.80M-$59.12M-$61.92M-$43.33M
Net income-$265.94M-$193.51M-$80.74M-$71.04M-$6.55M-$155.64M-$86.37M-$59.98M-$63.39M-$44.70M
Research & development$197.10M$127.64M$61.06M$53.46M$50.08M$28.69M$41.09M$36.92M$30.88M$27.06M
Weighted-average diluted sharesshares 187.24Mshares 158.27Mshares 85.60Mshares 82.64Mshares 82.16Mshares 60.75Mshares 45.27MUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-1.42$-1.22$-1.02$-0.97$-0.98$-2.56$-1.91UnavailableUnavailableUnavailable
Selling, general & administrative$118.30M$102.24M$74.49M$72.15M$67.07M$49.47M$46.61M$23.73M$32.51M$17.70M
General & administrative$64.38M$60.65M$33.94M$32.22M$31.88M$22.86M$22.12M$18.79M$15.51M$11.00M
Selling & marketing$53.92M$41.59M$40.55M$39.92M$35.19M$26.61M$24.49M$4.94M$17.00M$6.70M

Balance

OCULAR THERAPEUTIX, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$737.06M$392.10M$195.81M$102.30M$164.16M$228.06M$54.44M$54.06M$41.54M$32.94M
Total assets$808.06M$457.94M$252.06M$149.29M$204.89M$261.86M$78.74M$73.04M$55.43M$74.94M
Current assets$782.13M$440.99M$232.24M$129.63M$191.30M$246.16M$60.17M$56.19M$43.34M$69.90M
Total liabilities$153.75M$142.59M$160.93M$113.91M$116.89M$185.77M$82.37M$37.17M$29.28M$22.93M
Current liabilities$50.81M$41.35M$34.90M$31.40M$26.34M$26.66M$12.03M$9.16M$13.43M$8.30M
Total equity incl. NCI$654.31M$315.34M$91.13M$35.38M$88.00M$76.10M-$3.63M$35.88M$26.15M$52.01M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$3.56M$3.04M$2.30M$1.97M$1.25M$1.20M$954.00K$217.00K$122.00K$113.00K
Accounts receivable$30.65M$32.39M$26.18M$21.32M$21.14M$12.25M$2.55M$201.00K$226.00K$250.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.15M$4.18M$4.39M$5.12M$4.59M$2.71M$3.27M$2.96M$3.57M$2.12M

Cash flow

OCULAR THERAPEUTIX, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$204.88M-$134.68M-$70.23M-$59.60M-$65.55M-$53.55M-$77.58M-$49.23M-$50.47M-$34.00M
Capital expenditures$12.01M$1.29M$6.09M$3.72M$1.19M$841.00K$2.24M$1.89M$8.25M$1.92M
Investing cash flow-$11.88M-$1.29M-$6.09M-$3.72M-$1.19M-$841.00K-$2.24M-$1.89M$26.95M$37.07M
Financing cash flow$561.72M$332.11M$169.83M$1.45M$2.85M$228.01M$75.34M$68.64M$32.01M$585.00K
Net change in cash$344.96M$196.14M$93.51M-$61.86M-$63.89M$173.62M-$4.48M$17.52M$8.49M$3.65M
Stock-based compensation$43.18M$33.11M$17.82M$16.96M$14.98M$7.53M$8.76M$7.48M$7.32M$5.96M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$4.32M$3.79M$2.98M$2.11M$2.42M$2.77M$2.53M$2.29M$1.62M$881.00K

Derived

OCULAR THERAPEUTIX, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$216.89M-$135.96M-$76.32M-$63.32M-$66.74M-$54.40M-$79.82M-$51.12M-$58.72M-$35.92M
Gross margin87.3%91.2%91.0%91.2%89.9%88.0%45.0%76.6%76.2%Unavailable
Operating margin-519.8%-269.6%-141.0%-152.7%-179.3%-361.1%-2029.9%-2970.8%-3220.1%-2296.0%
FCF margin-417.5%-213.4%-130.6%-123.0%-153.4%-312.6%-1888.2%-2568.6%-3053.8%-1903.6%
SBC / revenue83.1%52.0%30.5%32.9%34.4%43.3%207.2%376.0%380.7%315.6%
Current ratio15.39x10.66x6.66x4.13x7.26x9.23x5.00x6.14x3.23x8.42x
Revenue YoY growth-18.5%9.0%13.5%18.3%150.1%311.7%112.4%3.5%1.9%Unavailable
Net margin-511.9%-303.7%-138.1%-138.0%-15.1%-894.3%-2043.3%-3014.0%-3296.2%-2369.0%
R&D / revenue379.4%200.3%104.5%103.8%115.1%164.9%972.1%1855.0%1605.8%1434.3%
CapEx / revenue23.1%2.0%10.4%7.2%2.7%4.8%52.9%94.9%429.1%101.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OCUL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-05View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2016-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.